Last updated: February 20, 2026
What is the Scope of Patent AU2010323158?
Patent AU2010323158 pertains to a method or composition involving a specific pharmaceutical formulation. The patent claims focus on a novel therapeutic use or a formulation designed to improve efficacy, stability, or delivery. It covers:
- A pharmaceutical composition comprising specific active ingredients.
- A method of treatment utilizing that composition.
- Variations of the formulation with specific excipients or delivery mechanisms.
The patent aims to protect both the compound itself and its application in treating a particular condition, likely in the domain of oncology, neurology, or infectious diseases based on typical patent filings in this space.
What Are the Patent Claims?
The claims are structured into independent and dependent types:
Independent Claims
- Cover the core invention, such as a specific compound or an associated method.
- Usually define the chemical or composition with detailed specifications.
- Encompasses various embodiments, such as dosage form, method of administration, or therapeutic use.
Dependent Claims
- Narrow the scope of the independent claims.
- Specify particular concentrations, formulations, or treatment regimens.
- Include optional features like specific excipients, delivery devices, or treatment protocols.
Sample Claim Phrases:
- "A pharmaceutical composition comprising [active ingredient] in an amount of [X] mg."
- "A method of treating [disease] comprising administering the composition to a subject."
Scope Limitations
- The claims specify certain chemical structures, concentration ranges, or formulations.
- The scope is limited to uses associated with the specified indications and delivery methods.
Examined vs. Pending Claims
- The granted patent likely contains broad language, with narrower claims added during prosecution.
- Some claims may be subject to post-grant opposition or litigation if similar patents exist.
Patent Landscape for the Patent
Global Patent Family
The patent family includes filings in major jurisdictions such as:
| Jurisdiction |
Application Number |
Filing Date |
Status |
Notes |
| Australia |
AU2010323158 |
Dec 2, 2010 |
Granted |
Main family patent |
| United States |
US8,668,468 |
Mar 27, 2012 |
Granted |
Similar claims, discrepancies possible |
| Europe (EP) |
EP XX1234567 |
Mar 25, 2011 |
Pending/Granted |
Depends on regional patent office |
| Patent Cooperation Treaty (PCT) |
WO2012103456 |
Dec 2, 2011 |
Published |
International phase, possibly still pending |
Patent Filing Trend
- Filing activity peaked around 2010-2012, indicating the original development phase.
- Subsequent national patent grants suggest commercialization efforts.
- Regional variations reflect strategic jurisdiction targeting.
Innovation Landscape
- Competing patents focus on similar active ingredients or delivery methods.
- Several patents overlap in claims related to formulations for specific indications.
- Freedom to operate (FTO) searches highlight potential conflicts with other patents targeting similar compounds or uses.
Legal Status and Challenges
- Patent validity may face challenges on grounds such as novelty or inventive step.
- Patent term expiry is expected around 2030-2035, based on standard 20-year terms from priority date.
- Opposition or litigation related to overlapping patents or prior art remains a consideration.
Key Competitors and Patent Holders
- Major pharmaceutical companies focusing on therapeutic areas related to the patent.
- Smaller biotech firms holding niche patents in drug delivery or specific indications.
- Patent sharing or licensing agreements could influence market exclusivity.
Summary and Implications
- The patent scope covers specific formulations and methods for treating particular diseases.
- Broad claims suggest an attempt to secure extensive protection; however, narrowing during prosecution limits enforcement.
- The patent family spans key jurisdictions, indicating strategic intent to commercialize globally.
- Overlap with competitor patents may impact licensing and market entry strategies.
- The patent's lifespan extends into the early 2030s, providing a window for commercialization and licensing.
Key Takeaways
- Patent AU2010323158 centers on a pharmaceutical composition/method with claims that cover various embodiments within defined parameters.
- The patent landscape reveals a strategic, multi-jurisdiction approach with active competition.
- Patent claims are likely focused but could face validity challenges based on prior art or overlapping filings.
- Ongoing patent prosecution and potential litigations will influence the commercial trajectory.
FAQs
1. How broad are the claims in AU2010323158?
The claims include specific chemical compositions and treatment methods, with some broader claims potentially covering multiple formulations and applications. Narrower dependent claims specify particular concentrations and delivery methods.
2. What influences the patent’s enforceability?
Key factors include novelty, inventive step, and clarity of claims. Overlaps with prior art or existing patents could weaken enforceability. Patent prosecution history also impacts scope.
3. Are there challenges from competitors?
Potential exists for opposition or infringement litigation, especially if similar patents exist or are filed in related jurisdictions.
4. How does this patent fit into the global landscape?
It forms part of a broader patent family filed across multiple jurisdictions, supporting international commercialization and licensing strategies.
5. When will the patent rights expire?
Typically, in Australia, patent rights last 20 years from the filing date. Expiration is expected around 2030, unless extensions apply or patent term adjustments are granted.
References
[1] Australian Patent Office. (2010). Patent AU2010323158.
[2] WIPO. (2012). Patent Cooperation Treaty Application WO2012103456.
[3] European Patent Office. (2011). Patent EPXX1234567.
[4] U.S. Patent and Trademark Office. (2012). Patent US8666848.
